Arrowhead Pharmaceuticals, Inc. (ARWR) — Fair Value Analysis

Base-case fair value (P50): $78.61 · Current price: $86.64 · Verdict: Fairly Valued

The Verdict on ARWR

Our Monte Carlo simulations indicate ARROWHEAD PHARMACEUTICALS INC (ARWR) is Fairly Valued at its current market price of $86.64. The median fair value (P50) derived from thousands of forward-looking scenarios stands at $78.61. This analysis suggests a minor -9.3% compared to the current trading price, positioning ARWR squarely within fair valuation territory. Investors should note this slight discount as part of a broader fair valuation, rather than an indication of significant over- or undervaluation.

How ARWR stacks up against peers

Despite the Fairly Valued verdict, ARWR maintains a strong quality tier, reflecting robust operational and financial health. This internal strength is a key input into our Monte Carlo simulations, underpinning the $78.61 fair value. While the sector information is not specifically defined for ARROWHEAD, its strong fundamental quality is a positive differentiator. This resilience helps stabilize its valuation profile, supporting the $78.61 even when the $86.64 shows a minor -9.3%.

What this means for investors

For investors considering ARWR, the Fairly Valued verdict based on our Monte Carlo simulations suggests that the current price of $86.64 accurately reflects the company's intrinsic value, with only a marginal -9.3%. While a modest upside scenario remains possible, our P50 target of $78.61 implies limited immediate catalysts for substantial price appreciation from current levels. For a comprehensive view of ARWR's potential price movements, including detailed bear-case and bull-case scenarios from our full Monte Carlo distribution, sign up for FairCurve to track ARWR's fair value as new fundamentals are released.